Cantor Fitzgerald Reiterates Overweight on ACADIA Pharmaceuticals, Maintains $37 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on ACADIA Pharmaceuticals (ACAD) with a maintained price target of $37.
April 30, 2024 | 2:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald maintains an Overweight rating on ACADIA Pharmaceuticals with a $37 price target.
The reiteration of an Overweight rating and a maintained price target of $37 by a reputable analyst suggests a positive outlook for ACADIA Pharmaceuticals, likely leading to increased investor confidence and potential upward movement in the stock's price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100